Remission frequency <i>versus</i> remission quality in transplant-eligible older patients. Comment on: “Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy <i>versus</i> liposomal cytarabine and daunorubicin”

Naif I. AlJohani

doi:10.3324/haematol.2026.301453

Comments

Remission frequency versus remission quality in transplant-eligible older patients. Comment on: “Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin”

Naif I. AlJohani

Adult Hematology and Hematopoietic Stem Cell Transplantation Section, King Faisal Specialist Hospital and Research Centre, Jeddah, ORCID: 0000-0003-4426-9434

Haematologica Early view Jul 16, 2026 https://doi.org/10.3324/haematol.2026.301453

Abstract

Not available.

Figures & Tables

Article Information

Early view : Comments

DOI

https://doi.org/10.3324/haematol.2026.301453

Published

2026-07-16

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

Copyright & Usage

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views

113

PDF Downloads

56

No Data

PlumX

Abstract

Figures & Tables

Article Information

Article Usage

Download Citation

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More